A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

Protocol No
PROTHENA-NEOD001-301
Staff Member
Anita D'Souza
Phase
III
Summary

The purpose of this study is to evaluate whether birtamimab, when given along with standard of
care chemotherapy, will improve survival in subjects with Mayo Stage IV AL amyloidosis.

Objective
Birtamimab plus SOC vs Placebo plus SOC in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL